POPULATION PHARMACOKINETIC ANALYSIS OF IGPRO10 IN JAPANESE PATIENTS WITH PRIMARY IMMUNODEFICIENCY.

被引：0
|
作者：
Luo, D. [1 ]
Tortorici, M. [1 ]
Hofmann, J. [1 ]
Rojavin, M. [1 ]
Baheti, G. [1 ]
机构：
[1] CSL Behring, King Of Prussia, PA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-057
引用
收藏
页码：S94 / S94
页数：1
相关论文
共 50 条
  • [1] Pharmacometric Analysis of IgPro10 in Japanese and Non-Japanese Patients With Primary Immunodeficiency
    Luo, Dandan
    Baheti, Gautam
    Tortorici, Michael A.
    Hofmann, Jutta
    Rojavin, Mikhail A.
    [J]. CLINICAL THERAPEUTICS, 2020, 42 (01) : 196 - 209
  • [2] Safety and tolerability of IgPro10 in Japanese primary immunodeficiency patients: a registrational study
    Tomohiro Morio
    Kenji Gotoh
    Tomoyuki Imagawa
    Kimio Morita
    Hidenori Ohnishi
    Kozo Yasui
    Jutta Hofmann
    John Philip Lawo
    Amgad Shebl
    Mikhail A. Rojavin
    [J]. International Journal of Hematology, 2021, 113 : 921 - 929
  • [3] Safety and tolerability of IgPro10 in Japanese primary immunodeficiency patients: a registrational study
    Morio, Tomohiro
    Gotoh, Kenji
    Imagawa, Tomoyuki
    Morita, Kimio
    Ohnishi, Hidenori
    Yasui, Kozo
    Hofmann, Jutta
    Lawo, John Philip
    Shebl, Amgad
    Rojavin, Mikhail A.
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (06) : 921 - 929
  • [4] Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra®) dosing in patients with primary immunodeficiency
    Zhang, Ying
    Baheti, Gautam
    Chapdelaine, Hugo
    Hofmann, Jutta
    Rojavin, Mikhail
    Tortorici, Michael
    Haddad, Elie
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 81
  • [5] Infections in Secondary Immunodeficiency Patients Treated with IgPro10: A Real-Word Analysis of Patients, Including Those with Hematological Malignancies
    Lahue, Betsy
    Mallick, Rajiv
    Zhang, Xiang
    Koenig, Andrew S.
    Espinoza, Gabriela
    [J]. BLOOD, 2021, 138
  • [6] Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency
    Rojavin, Mikhail A.
    Chapdelaine, Hugo
    Tortorici, Michael A.
    Praus, Michaela
    Baheti, Gautam
    Zhang, Ying
    Hofmann, Jutta
    Labrosse, Roxane
    Dicaire, Renee
    Haddad, Elie
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (06): : 664 - 670
  • [7] Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections
    Lahue, Betsy J.
    Mallick, Rajiv
    Zhang, Xiang
    Heidt, Julien
    Song, Yufei
    Koenig, Andrew S.
    Espinoza, Gabriela
    [J]. IMMUNOTHERAPY, 2022, 14 (15) : 1245 - 1261
  • [8] Efficacy and tolerability of Privigen® (IgPro10) in primary and secondary immunodeficiencies - A multicenter observational study
    Otremba, B.
    Slawik, H. R.
    Tschechne, B.
    Lotichius, P.
    Pfruender, D.
    [J]. PROCEEDINGS OF THE 15TH MEETING OF THE EUROPEAN SOCIETY IMMUNODEFICIENCIES (ESID), 2013, : 15 - 18
  • [9] Cost-minimization Analysis of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients With Primary Immunodeficiency
    Igarashi, Ataru
    Kanegane, Hirokazu
    Kobayashi, Midori
    Miyawaki, Toshio
    Tsutani, Kiichiro
    [J]. CLINICAL THERAPEUTICS, 2014, 36 (11) : 1616 - 1624
  • [10] EFFICACY AND TOLERABILITY OF PRIVIGEN® (IGPRO10) IN PRIMARY AND SECONDARY IMMUNODEFICIENCIES - A MULTICENTER OBSERVATIONAL STUDY
    Otremba, B.
    Slawik, H. R.
    Tschechne, B.
    Lotichius, P.
    Pfruender, D.
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 158 - 159
12345